IL31 and chronic kidney disease: IL-31 Antagonism & Edema Monitoring: Nemolizumab’s IL-31 pathway blockade may benefit atopic phenotypes but necessitates intensified fluid retention monitoring during treatment initiation, especially in patients with chronic kidney disease or heart failure.